Novartis to conduct additional trial of Rasilez

Novartis Inc. plans to expand the clinical trial program with Rasilez (aliskiren) to study organ protection potential beyond the already shown powerful reduction of blood pressure, according to Novartis Korea.

Rasilez is the first-in-class oral direct renin inhibitor. The development of Rasilez is the result of over 20 years of research on renin.

Novartis announced details of two new long...